|
US3536809A
(en)
|
1969-02-17 |
1970-10-27 |
Alza Corp |
Medication method
|
|
US3598123A
(en)
|
1969-04-01 |
1971-08-10 |
Alza Corp |
Bandage for administering drugs
|
|
US3845770A
(en)
|
1972-06-05 |
1974-11-05 |
Alza Corp |
Osmatic dispensing device for releasing beneficial agent
|
|
US3916899A
(en)
|
1973-04-25 |
1975-11-04 |
Alza Corp |
Osmotic dispensing device with maximum and minimum sizes for the passageway
|
|
US4008719A
(en)
|
1976-02-02 |
1977-02-22 |
Alza Corporation |
Osmotic system having laminar arrangement for programming delivery of active agent
|
|
US4271164A
(en)
|
1979-04-16 |
1981-06-02 |
Warner-Lambert Company |
6-Substituted-arylpyrido[2,3-d]pyrimidin-7-amines and derivatives
|
|
KR890002631B1
(ko)
|
1984-10-04 |
1989-07-21 |
몬산토 캄파니 |
생물학적으로 활성인 소마토트로핀을 지속적으로 유리하는 조성물
|
|
IE58110B1
(en)
|
1984-10-30 |
1993-07-14 |
Elan Corp Plc |
Controlled release powder and process for its preparation
|
|
US5073543A
(en)
|
1988-07-21 |
1991-12-17 |
G. D. Searle & Co. |
Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
|
|
IT1229203B
(it)
|
1989-03-22 |
1991-07-25 |
Bioresearch Spa |
Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
|
|
PH30995A
(en)
|
1989-07-07 |
1997-12-23 |
Novartis Inc |
Sustained release formulations of water soluble peptides.
|
|
US5120548A
(en)
|
1989-11-07 |
1992-06-09 |
Merck & Co., Inc. |
Swelling modulated polymeric drug delivery device
|
|
US5733566A
(en)
|
1990-05-15 |
1998-03-31 |
Alkermes Controlled Therapeutics Inc. Ii |
Controlled release of antiparasitic agents in animals
|
|
US5580578A
(en)
|
1992-01-27 |
1996-12-03 |
Euro-Celtique, S.A. |
Controlled release formulations coated with aqueous dispersions of acrylic polymers
|
|
TW333456B
(en)
|
1992-12-07 |
1998-06-11 |
Takeda Pharm Ind Co Ltd |
A pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide.
|
|
US5591767A
(en)
|
1993-01-25 |
1997-01-07 |
Pharmetrix Corporation |
Liquid reservoir transdermal patch for the administration of ketorolac
|
|
US6087324A
(en)
|
1993-06-24 |
2000-07-11 |
Takeda Chemical Industries, Ltd. |
Sustained-release preparation
|
|
IT1270594B
(it)
|
1994-07-07 |
1997-05-07 |
Recordati Chem Pharm |
Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
|
|
GB9420168D0
(en)
*
|
1994-10-06 |
1994-11-23 |
Boots Co Plc |
Therapeutic agents
|
|
DE69632684T2
(de)
|
1995-06-27 |
2005-06-09 |
Takeda Pharmaceutical Co. Ltd. |
Verfahren zur herstellung von zubereitungen mit verzögerter freisetzung
|
|
TW448055B
(en)
|
1995-09-04 |
2001-08-01 |
Takeda Chemical Industries Ltd |
Method of production of sustained-release preparation
|
|
JP2909418B2
(ja)
|
1995-09-18 |
1999-06-23 |
株式会社資生堂 |
薬物の遅延放出型マイクロスフイア
|
|
US5980945A
(en)
|
1996-01-16 |
1999-11-09 |
Societe De Conseils De Recherches Et D'applications Scientifique S.A. |
Sustained release drug formulations
|
|
US6264970B1
(en)
|
1996-06-26 |
2001-07-24 |
Takeda Chemical Industries, Ltd. |
Sustained-release preparation
|
|
US6419961B1
(en)
|
1996-08-29 |
2002-07-16 |
Takeda Chemical Industries, Ltd. |
Sustained release microcapsules of a bioactive substance and a biodegradable polymer
|
|
CA2217134A1
(en)
|
1996-10-09 |
1998-04-09 |
Sumitomo Pharmaceuticals Co., Ltd. |
Sustained release formulation
|
|
ES2221019T3
(es)
|
1996-10-31 |
2004-12-16 |
Takeda Chemical Industries, Ltd. |
Preparacion de liberacion mantenida.
|
|
EP0946169B1
(en)
|
1996-12-20 |
2003-02-26 |
Takeda Chemical Industries, Ltd. |
Method of producing a sustained-release preparation
|
|
US5891474A
(en)
|
1997-01-29 |
1999-04-06 |
Poli Industria Chimica, S.P.A. |
Time-specific controlled release dosage formulations and method of preparing same
|
|
ATE344791T1
(de)
|
1997-07-01 |
2006-11-15 |
Warner Lambert Co |
2-(4-brom or 4-iod phenylamino)benzoesäurederivate und ihre anwendung als mek-inhibitoren
|
|
AU742999B2
(en)
*
|
1997-08-20 |
2002-01-17 |
Warner-Lambert Company |
Naphthyridinones for inhibiting protein tyrosine kinase and cell cycle kinase mediated cellular proliferation
|
|
JP2910748B2
(ja)
|
1997-11-12 |
1999-06-23 |
日本電気株式会社 |
異質同軸部材の端面の球状加工装置及びその方法
|
|
US6613358B2
(en)
|
1998-03-18 |
2003-09-02 |
Theodore W. Randolph |
Sustained-release composition including amorphous polymer
|
|
KR19990085365A
(ko)
|
1998-05-16 |
1999-12-06 |
허영섭 |
지속적으로 약물 조절방출이 가능한 생분해성 고분자 미립구 및그 제조방법
|
|
JP2002534515A
(ja)
|
1999-01-13 |
2002-10-15 |
ワーナー−ランバート・カンパニー |
１−複素環置換されたジアリールアミン
|
|
US6248363B1
(en)
|
1999-11-23 |
2001-06-19 |
Lipocine, Inc. |
Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
|
|
SG2013013339A
(en)
|
2002-03-13 |
2014-12-30 |
Array Biopharma Inc |
N3 alkylated benzimidazole derivatives as mek inhibitors
|
|
AU2003225161A1
(en)
|
2002-04-24 |
2003-11-10 |
Koo, Han-Mo |
Enhancement of human epidermal melanogenesis
|
|
RU2324695C2
(ru)
*
|
2002-08-06 |
2008-05-20 |
Ф.Хоффманн-Ля Рош Аг |
6-АЛКОКСИПИРИДОПИРИМИДИНЫ И ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, ОБЛАДАЮЩАЯ АКТИВНОСТЬЮ ИНГИБИТОРОВ КИНАЗЫ МАР р38
|
|
KR101190912B1
(ko)
|
2003-11-19 |
2012-10-12 |
어레이 바이오파마 인크. |
Ｍｅｋ의 헤테로시클릭 억제제 및 그의 사용 방법
|
|
JP2008503446A
(ja)
|
2004-05-06 |
2008-02-07 |
プレキシコン，インコーポレーテッド |
Ｐｄｅ４ｂ阻害剤及びその使用
|
|
KR100883289B1
(ko)
|
2004-06-11 |
2009-02-11 |
니뽄 다바코 산교 가부시키가이샤 |
암 치료용5-아미노-2,4,7-트리옥소-3,4,7,8-테트라히드로-2ｈ-피리도[2,3-ｄ]피리미딘 유도체 및 관련 화합물
|
|
US7674907B2
(en)
|
2004-07-23 |
2010-03-09 |
Amgen Inc. |
Furanopyridine derivatives and methods of use
|
|
ES2444866T3
(es)
|
2004-10-20 |
2014-02-27 |
Merck Serono Sa |
Derivados de 3-arilamino piridina
|
|
WO2006083979A2
(en)
|
2005-02-02 |
2006-08-10 |
Nexgenix Pharmaceuticals, L.L.C. |
Local treatment of neurofibromas
|
|
MY153898A
(en)
|
2005-06-22 |
2015-04-15 |
Plexxikon Inc |
Compounds and methods for kinase modulation, and indications therefor
|
|
NZ567140A
(en)
|
2005-10-07 |
2011-09-30 |
Exelixis Inc |
Azetidines as MEK inhibitors for the treatment of proliferative diseases
|
|
GB0601962D0
(en)
|
2006-01-31 |
2006-03-15 |
Ucb Sa |
Therapeutic agents
|
|
WO2007123939A2
(en)
|
2006-04-19 |
2007-11-01 |
Laboratoires Serono S.A. |
Novel arylamino n-heteraryls as mek inhibitors
|
|
GB0616214D0
(en)
|
2006-08-15 |
2006-09-27 |
Ucb Sa |
Therapeutic Agents
|
|
CA2658725A1
(en)
|
2006-08-16 |
2008-02-21 |
Exelixis, Inc. |
Using pi3k and mek modulators in treatments of cancer
|
|
WO2008024724A1
(en)
|
2006-08-21 |
2008-02-28 |
Genentech, Inc. |
Aza-benzothiophenyl compounds and methods of use
|
|
CA2660546A1
(en)
|
2006-08-21 |
2008-02-28 |
Genentech, Inc. |
Aza-benzofuranyl compounds and methods of use
|
|
CA2666398C
(en)
|
2006-10-17 |
2015-08-18 |
Ed Kisak |
Diclofenac gel
|
|
EP2113500A1
(en)
|
2006-10-31 |
2009-11-04 |
Takeda Pharmaceutical Company Limited |
MAPK/ERK kinase inhibitors
|
|
CA2672327A1
(en)
|
2006-11-30 |
2008-06-05 |
Genentech, Inc. |
Aza-indolyl compounds and methods of use
|
|
JO2985B1
(ar)
|
2006-12-20 |
2016-09-05 |
Takeda Pharmaceuticals Co |
مثبطات كينازmapk/erk
|
|
JP5592253B2
(ja)
|
2007-05-11 |
2014-09-17 |
バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング |
過剰増殖性疾患およびマイトジェン細胞外キナーゼ活性関連性疾患を治療するための置換フェニルアミノ−ベンゼン誘導体
|
|
US20080312307A1
(en)
|
2007-05-25 |
2008-12-18 |
Takeda Pharmaceutical Company Limited |
Mapk/erk kinase inhibitors
|
|
GB0714384D0
(en)
|
2007-07-23 |
2007-09-05 |
Ucb Pharma Sa |
theraputic agents
|
|
CA2708176A1
(en)
|
2007-12-21 |
2009-07-02 |
Genentech, Inc. |
Azaindolizines and methods of use
|
|
WO2009093008A1
(en)
|
2008-01-21 |
2009-07-30 |
Ucb Pharma S.A. |
Thieno-pyridine derivatives as mek inhibitors
|
|
GB0801080D0
(en)
|
2008-01-21 |
2008-02-27 |
Ucb Pharma Sa |
Therapeutic agents
|
|
GB0801081D0
(en)
|
2008-01-21 |
2008-02-27 |
Ucb Pharma Sa |
Therapeutic agents
|
|
WO2009146034A2
(en)
|
2008-03-31 |
2009-12-03 |
Takeda Pharmaceutical Company Limited |
Mapk/erk kinase inhibitors and methods of use thereof
|
|
GB0811304D0
(en)
|
2008-06-19 |
2008-07-30 |
Ucb Pharma Sa |
Therapeutic agents
|
|
CN102458402B
(zh)
|
2009-06-12 |
2013-10-02 |
百时美施贵宝公司 |
用作激酶调节剂的烟酰胺化合物
|
|
DE102010012594A1
(de)
|
2010-03-23 |
2011-09-29 |
Beiersdorf Ag |
Kosmetische oder dermatologische Zubereitungen mit einem Gehalt an einem oder mehreren Thiazolderivaten
|
|
US9422262B2
(en)
|
2010-09-24 |
2016-08-23 |
The Broad Institute, Inc. |
Compounds and methods for treating diseases mediated by protease activated receptors
|
|
CN103189062B
(zh)
|
2010-11-05 |
2016-03-23 |
霍夫曼-拉罗奇有限公司 |
活性药物化合物用于治疗中枢神经系统病症的用途
|
|
WO2012099968A1
(en)
|
2011-01-19 |
2012-07-26 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for treating skin cancer associated diseases
|
|
GB201104267D0
(en)
|
2011-03-14 |
2011-04-27 |
Cancer Rec Tech Ltd |
Pyrrolopyridineamino derivatives
|
|
EP2757092A4
(en)
|
2011-06-17 |
2015-09-23 |
Sinochem Corp |
SUBSTITUTED CYANANILIN COMPOUNDS, METHOD OF MANUFACTURING THEREOF AND USE THEREOF
|
|
US9357781B2
(en)
|
2013-05-03 |
2016-06-07 |
Inscent, Inc. |
Honeybee repellents and uses thereof
|
|
US10835513B2
(en)
|
2013-06-28 |
2020-11-17 |
The Regents Of The University Of California |
Methods and treatments for the learning and memory deficits associated with Noonan syndrome
|
|
US9572828B2
(en)
|
2013-07-18 |
2017-02-21 |
The Board Of Regents Of The University Of Texas System |
Treatment for melanoma
|
|
EP3290407B1
(en)
*
|
2013-10-18 |
2020-01-01 |
Celgene Quanticel Research, Inc |
Bromodomain inhibitors
|
|
CN105384754B
(zh)
|
2014-09-02 |
2018-04-20 |
上海科州药物研发有限公司 |
作为蛋白激酶抑制剂的杂环类化合物及其制备方法和用途
|
|
EP3383912A4
(en)
|
2015-11-30 |
2019-11-06 |
Ignyta, Inc. |
TOPICAL FORMULATIONS
|
|
EP3301094A1
(en)
|
2016-09-30 |
2018-04-04 |
Mutabilis |
Heterocyclic compounds and their use in preventing or treating bacterial infections
|
|
DE102016225694A1
(de)
|
2016-12-21 |
2018-06-21 |
Robert Bosch Gmbh |
Verfahren zur Verstärkung der Bremskraft in einer elektronisch schlupfregelbaren Fahrzeugbremsanlage und elektronisch schlupfregelbare Fahrzeugbremsanlage
|
|
JP7212956B2
(ja)
|
2017-05-19 |
2023-01-26 |
エヌフレクション セラピューティクス インコーポレイテッド |
皮膚障害の処置用のピロロピリジン－アニリン化合物
|
|
ES2913213T3
(es)
|
2017-05-19 |
2022-06-01 |
Nflection Therapeutics Inc |
Compuestos heteroaromáticos de anilina condensados para el tratamiento de trastornos dérmicos
|
|
WO2019139970A1
(en)
|
2018-01-09 |
2019-07-18 |
Duke University |
Topical administration of mek inhibiting agents for the treatment of skin disorders
|
|
WO2020101878A2
(en)
|
2018-10-29 |
2020-05-22 |
The Johns Hopkins University |
Rasopathy treatment
|
|
EP3883552B1
(en)
|
2018-11-20 |
2025-04-09 |
NFlection Therapeutics, Inc. |
Cyanoaryl-aniline compounds for treatment of dermal disorders
|
|
CN113645964B
(zh)
|
2018-11-20 |
2024-10-11 |
恩福莱克逊治疗有限公司 |
用于胎记治疗的芳基苯胺和杂芳基苯胺化合物
|
|
WO2020106304A1
(en)
|
2018-11-20 |
2020-05-28 |
Nflection Therapeutics, Inc. |
Topical formulations
|
|
CN113660931B
(zh)
|
2018-11-20 |
2024-10-11 |
恩福莱克逊治疗有限公司 |
用于治疗皮肤癌的芳基苯胺和杂芳基苯胺化合物
|
|
CN113473986B
(zh)
|
2018-11-20 |
2024-10-11 |
恩福莱克逊治疗有限公司 |
用于治疗皮肤疾病萘啶酮苯胺化合物
|
|
WO2020106305A1
(en)
|
2018-11-20 |
2020-05-28 |
Nflection Therapeutics, Inc. |
Thienyl-aniline compounds for treatment of dermal disorders
|
|
JP2023547040A
(ja)
|
2020-09-24 |
2023-11-09 |
エヌフレクション セラピューティクス インコーポレイテッド |
ピロロピリジン－アニリン化合物による、認知機能不全の処置方法
|
|
AU2022210443A1
(en)
|
2021-01-21 |
2023-09-07 |
Nflection Therapeutics, Inc. |
Processes for preparing pyrrolopyridine-aniline compounds
|
|
CN117157065A
(zh)
|
2021-01-21 |
2023-12-01 |
恩福莱克逊治疗有限公司 |
吡咯并吡啶-苯胺化合物的晶型
|